Biomea Fusion (BMEA) Competitors

$1.46 -0.02 (-1.01%)

As of 02:20 PM Eastern

BMEA vs. ADCT, ENTA, AGMB, AVIR, and CABA

Should you buy Biomea Fusion stock or one of its competitors? MarketBeat compares Biomea Fusion with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biomea Fusion include ADC Therapeutics (ADCT), Enanta Pharmaceuticals (ENTA), AgomAb Therapeutics (AGMB), Atea Pharmaceuticals (AVIR), and Cabaletta Bio (CABA). These companies are all part of the "pharmaceutical products" industry.

How does Biomea Fusion compare to ADC Therapeutics?

Biomea Fusion (NASDAQ:BMEA) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Biomea Fusion had 10 more articles in the media than ADC Therapeutics. MarketBeat recorded 11 mentions for Biomea Fusion and 1 mentions for ADC Therapeutics. Biomea Fusion's average media sentiment score of 0.98 beat ADC Therapeutics' score of -0.49 indicating that Biomea Fusion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biomea Fusion has higher earnings, but lower revenue than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$1.31	N/A
ADC Therapeutics	$81.36M	5.31	-$142.62M	-$1.05	N/A

Biomea Fusion has a beta of -0.32, suggesting that its share price is 132% less volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.83, suggesting that its share price is 83% more volatile than the broader market.

96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are held by institutional investors. 18.4% of Biomea Fusion shares are held by insiders. Comparatively, 5.4% of ADC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Biomea Fusion has a net margin of 0.00% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
ADC Therapeutics	-173.02%	N/A	-44.70%

Biomea Fusion currently has a consensus price target of $8.29, indicating a potential upside of 465.58%. ADC Therapeutics has a consensus price target of $8.00, indicating a potential upside of 135.64%. Given Biomea Fusion's stronger consensus rating and higher probable upside, equities analysts plainly believe Biomea Fusion is more favorable than ADC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
ADC Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Biomea Fusion beats ADC Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Biomea Fusion compare to Enanta Pharmaceuticals?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

In the previous week, Biomea Fusion had 5 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 11 mentions for Biomea Fusion and 6 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.98 equaled Biomea Fusion'saverage media sentiment score.

Company	Overall Sentiment
Enanta Pharmaceuticals	Positive
Biomea Fusion	Positive

Biomea Fusion has lower revenue, but higher earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$69.21M	5.84	-$81.89M	-$2.59	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$1.31	N/A

Enanta Pharmaceuticals presently has a consensus price target of $20.29, indicating a potential upside of 45.52%. Biomea Fusion has a consensus price target of $8.29, indicating a potential upside of 465.58%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts plainly believe Biomea Fusion is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Enanta Pharmaceuticals has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.32, suggesting that its share price is 132% less volatile than the broader market.

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Comparatively, 18.4% of Biomea Fusion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Biomea Fusion has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. Enanta Pharmaceuticals' return on equity of -68.72% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-68.72%	-20.41%
Biomea Fusion	N/A	-265.37%	-103.96%

Summary

Biomea Fusion beats Enanta Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Biomea Fusion compare to AgomAb Therapeutics?

Biomea Fusion (NASDAQ:BMEA) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$1.31	N/A
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A

In the previous week, Biomea Fusion had 7 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 11 mentions for Biomea Fusion and 4 mentions for AgomAb Therapeutics. Biomea Fusion's average media sentiment score of 0.98 beat AgomAb Therapeutics' score of 0.30 indicating that Biomea Fusion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

96.7% of Biomea Fusion shares are owned by institutional investors. 18.4% of Biomea Fusion shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Biomea Fusion presently has a consensus target price of $8.29, indicating a potential upside of 465.58%. AgomAb Therapeutics has a consensus target price of $32.00, indicating a potential upside of 191.07%. Given Biomea Fusion's stronger consensus rating and higher possible upside, research analysts plainly believe Biomea Fusion is more favorable than AgomAb Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

AgomAb Therapeutics' return on equity of 0.00% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
AgomAb Therapeutics	N/A	N/A	N/A

Summary

Biomea Fusion beats AgomAb Therapeutics on 8 of the 10 factors compared between the two stocks.

How does Biomea Fusion compare to Atea Pharmaceuticals?

Biomea Fusion (NASDAQ:BMEA) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 18.4% of Biomea Fusion shares are held by insiders. Comparatively, 18.1% of Atea Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Biomea Fusion had 3 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 11 mentions for Biomea Fusion and 8 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.02 beat Biomea Fusion's score of 0.98 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atea Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biomea Fusion has a beta of -0.32, meaning that its share price is 132% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

Biomea Fusion presently has a consensus price target of $8.29, indicating a potential upside of 465.58%. Given Biomea Fusion's stronger consensus rating and higher possible upside, equities research analysts clearly believe Biomea Fusion is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Atea Pharmaceuticals' return on equity of -53.22% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
Atea Pharmaceuticals	N/A	-53.22%	-48.44%

Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$1.31	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$1.94	N/A

Summary

Biomea Fusion beats Atea Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Biomea Fusion compare to Cabaletta Bio?

Cabaletta Bio (NASDAQ:CABA) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Biomea Fusion had 5 more articles in the media than Cabaletta Bio. MarketBeat recorded 11 mentions for Biomea Fusion and 6 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 1.08 beat Biomea Fusion's score of 0.98 indicating that Cabaletta Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cabaletta Bio is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$2.28	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$1.31	N/A

96.7% of Biomea Fusion shares are owned by institutional investors. 6.4% of Cabaletta Bio shares are owned by company insiders. Comparatively, 18.4% of Biomea Fusion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cabaletta Bio's return on equity of -121.73% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-121.73%	-90.19%
Biomea Fusion	N/A	-265.37%	-103.96%

Cabaletta Bio has a beta of 3.18, meaning that its stock price is 218% more volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.32, meaning that its stock price is 132% less volatile than the broader market.

Cabaletta Bio currently has a consensus price target of $17.00, indicating a potential upside of 376.06%. Biomea Fusion has a consensus price target of $8.29, indicating a potential upside of 465.58%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts clearly believe Biomea Fusion is more favorable than Cabaletta Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Biomea Fusion beats Cabaletta Bio on 9 of the 14 factors compared between the two stocks.

Get Biomea Fusion News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMEA vs. The Competition

Export

Metric	Biomea Fusion	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$105.92M	$3.40B	$6.29B	$12.48B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-2.15	18.81	20.91	25.60
Price / Sales	N/A	284.65	548.78	75.41
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	5.63	6.78	9.87	6.72
Net Income	-$61.80M	$24.11M	$3.55B	$333.73M
7 Day Performance	-10.12%	0.22%	-0.24%	0.38%
1 Month Performance	-24.87%	1.08%	1.44%	4.02%
1 Year Performance	0.34%	78.09%	41.01%	36.37%

Biomea Fusion Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMEA Biomea Fusion	2.7994 of 5 stars	$1.47 -1.0%	$8.29 +465.6%	-9.2%	$105.92M	N/A	N/A	50	Earnings Report Analyst Revision
ADCT ADC Therapeutics	2.1417 of 5 stars	$3.50 -0.1%	$8.00 +128.9%	+163.3%	$445.17M	$81.36M	N/A	310
ENTA Enanta Pharmaceuticals	2.0542 of 5 stars	$15.46 +0.8%	$20.29 +31.2%	+168.3%	$445.16M	$65.32M	N/A	160	Positive News Earnings Report Analyst Revision High Trading Volume
AGMB AgomAb Therapeutics	N/A	$12.18 +0.4%	$32.00 +162.7%	N/A	$441.37M	N/A	N/A	62	News Coverage Short Interest Increase
AVIR Atea Pharmaceuticals	1.109 of 5 stars	$5.41 -0.4%	N/A	+73.8%	$434.55M	N/A	N/A	70	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BMEA) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biomea Fusion (BMEA) Competitors

BMEA vs. ADCT, ENTA, AGMB, AVIR, and CABA

How does Biomea Fusion compare to ADC Therapeutics?

Summary

How does Biomea Fusion compare to Enanta Pharmaceuticals?

Summary

How does Biomea Fusion compare to AgomAb Therapeutics?

Summary

How does Biomea Fusion compare to Atea Pharmaceuticals?

Summary

How does Biomea Fusion compare to Cabaletta Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA vs. The Competition

Biomea Fusion Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biomea Fusion (BMEA) Competitors

BMEA vs. ADCT, ENTA, AGMB, AVIR, and CABA

How does Biomea Fusion compare to ADC Therapeutics?

Does the media prefer BMEA or ADCT?

Which has better earnings & valuation, BMEA or ADCT?

Which has more volatility & risk, BMEA or ADCT?

Do institutionals and insiders hold more shares of BMEA or ADCT?

Is BMEA or ADCT more profitable?

Do analysts recommend BMEA or ADCT?

Summary

How does Biomea Fusion compare to Enanta Pharmaceuticals?

Does the media refer more to ENTA or BMEA?

Which has preferable valuation and earnings, ENTA or BMEA?

Do analysts rate ENTA or BMEA?

Which has more volatility & risk, ENTA or BMEA?

Do institutionals & insiders believe in ENTA or BMEA?

Is ENTA or BMEA more profitable?

Summary

How does Biomea Fusion compare to AgomAb Therapeutics?

Which has stronger earnings and valuation, BMEA or AGMB?

Does the media favor BMEA or AGMB?

Do institutionals & insiders believe in BMEA or AGMB?

Do analysts rate BMEA or AGMB?

Is BMEA or AGMB more profitable?

Summary

How does Biomea Fusion compare to Atea Pharmaceuticals?

Do institutionals and insiders have more ownership in BMEA or AVIR?

Does the media favor BMEA or AVIR?

Which has more risk and volatility, BMEA or AVIR?

Do analysts recommend BMEA or AVIR?

Is BMEA or AVIR more profitable?

Which has stronger valuation and earnings, BMEA or AVIR?

Summary

How does Biomea Fusion compare to Cabaletta Bio?

Does the media refer more to CABA or BMEA?

Which has higher earnings and valuation, CABA or BMEA?

Do institutionals & insiders have more ownership in CABA or BMEA?

Is CABA or BMEA more profitable?

Which has more volatility & risk, CABA or BMEA?

Do analysts rate CABA or BMEA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA vs. The Competition

Biomea Fusion Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools